Sepp-Lorenzino Laura
Known title: EVP, Chief Scientific OfficerCIK: 0001777421
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Intellia Therapeutics Appoints New Chief Medical Officer. Intellia Therapeutics announced the appointment of Jing L. Marantz as its new Chief Medical Officer. This leadership change occurred as the stock recently rose 7.6%, moving away from recent support levels. The news highlights a strategic shift in the company's medical leadership during a period of increased market activity.
Transaction History
| TSHA | ▲ Buy | Grant | 21,335 | $0 | 6/1/2026 | View on chart |
| TSHA | ▲ Buy | Grant | 56,623 | $0 | 6/2/2025 | View on chart |
| NTLA | ▼ Sell | Open Market | 8,966 | $109K | 1/3/2025 | View on chart |
| NTLA | ▲ Buy | Option Exercise | 3,500 | — | 1/1/2025 | View on chart |
| TSHA | ▲ Buy | Grant | 49,220 | $0 | 5/29/2024 | View on chart |
| NTLA | ▲ Buy | Grant | 37,966 | $0 | 3/1/2024 | View on chart |
| NTLA | ▼ Sell | Open Market | 1,608 | $46K | 1/8/2024 | View on chart |
| NTLA | ▼ Sell | Open Market | 667 | $20K | 1/8/2024 | View on chart |
| NTLA | ▼ Sell | Open Market | 5,532 | $163K | 1/3/2024 | View on chart |
| NTLA | ▲ Buy | Option Exercise | 3,500 | — | 1/1/2024 | View on chart |
| NTLA | ▲ Buy | Grant | 29,938 | $0 | 3/1/2023 | View on chart |
| NTLA | ▼ Sell | Open Market | 1,641 | $63K | 1/5/2023 | View on chart |
| NTLA | ▼ Sell | Open Market | 689 | $27K | 1/5/2023 | View on chart |
| NTLA | ▼ Sell | Open Market | 2,508 | $93K | 1/4/2023 | View on chart |
| NTLA | ▲ Buy | Option Exercise | 3,500 | — | 1/1/2023 | View on chart |
| NTLA | ▲ Buy | Grant | 13,816 | $0 | 3/1/2022 | View on chart |
| NTLA | ▼ Sell | Open Market | 1,148 | $129K | 1/1/2022 | View on chart |
| NTLA | ▲ Buy | Option Exercise | 3,500 | — | 1/1/2022 | View on chart |
| NTLA | ▼ Sell | Open Market | 16,115 | $2.5M | 8/30/2021 | View on chart |
| NTLA | ▲ Buy | Option Exercise | 27,000 | $362K | 8/30/2021 | View on chart |
| NTLA | ▲ Buy | Option Exercise | 70,000 | $998K | 8/30/2021 | View on chart |
| NTLA | ▼ Sell | Open Market | 15,839 | $2.4M | 8/30/2021 | View on chart |
| NTLA | ▼ Sell | Open Market | 20,645 | $3.2M | 8/30/2021 | View on chart |
| NTLA | ▼ Sell | Open Market | 28,669 | $4.4M | 8/30/2021 | View on chart |
| NTLA | ▼ Sell | Open Market | 7,425 | $1.2M | 8/30/2021 | View on chart |
| NTLA | ▼ Sell | Open Market | 3,932 | $620K | 8/30/2021 | View on chart |
| NTLA | ▼ Sell | Open Market | 1,515 | $241K | 8/30/2021 | View on chart |
| NTLA | ▼ Sell | Open Market | 2,653 | $424K | 8/30/2021 | View on chart |
| NTLA | ▼ Sell | Open Market | 207 | $33K | 8/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
TSHA Valuation Debate Highlights Split Views
Recent articles discuss conflicting views on Taysha Gene Therapies' valuation, with some suggesting the stock is above fair value based on book value, while others argue it may be undervalued. This debate occurs while the stock trades near its 52-week low, reflecting significant uncertainty among investors regarding the company's true worth.
TSHA Valuation Debate Highlights Split Views. Recent articles discuss conflicting views on Taysha Gene Therapies' valuation, with some suggesting the stock is above fair value based on book value, while others argue it may be undervalued. This debate occurs while the stock trades near its 52-week low, reflecting significant uncertainty among investors regarding the company's true worth.